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Background: Whilst the benefit of adjuvant radiotherapy in gastric cancer is 
known, the optimal means of delivery, including two dimensional conventional, 
three dimensional conformal radiotherapy, intensity modulated radiotherapy 
and volumetric modulated arc therapy is less certain. The purpose of this study 
is to assess and compare volumetric modulated arc therapy (VMAT) and three 
dimensional conformal radiotherapy (3DCRT) plans in adjuvant radiation of 
gastric cancer. Methods and materials: 8 patients who received adjuvant 
radiotherapy for gastric cancer using a 3DCRT technique were replanned with 
VMAT. The same CT data sets and contoured structures were used. The 
parameters used to compare planning target volume coverage included 
conformity index, uniformity index, homogeneity index, maximum dose and 
percentage of target volume receiving at least 95% of prescribed dose. The 
parameters used to compare organ at risk sparing included mean dose, 
maximum dose and the percentage of the volume of the organ at risk receiving 
more than its tolerance dose as defined by QUANTEC. Statistical analysis was 
performed with a paired t-test.  Results: VMAT achieved better target volume 
coverage and improved conformity and uniformity indexes. VMAT achieved 
decreased percentage of the volume of the liver receiving more than its 
tolerance dose as well as maximum dose but no difference in mean dose. There 
was no difference between VMAT and 3DCRT for the left and right kidneys and 
spinal cord in terms of the defined parameters. Conclusion: This study showed 
that VMAT is superior to 3DCRT for radiotherapy in the adjuvant setting for 
gastric cancer with regard to target volume coverage as well as liver sparing. 
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However, there was no benefit for other organs at risk, namely the left and right 
kidneys and spinal cord. Clinical studies are required to further define the 
benefit of VMAT in adjuvant radiotherapy for gastric cancer.  
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Introduction 
Gastric cancer remains one of the leading causes of cancer mortality worldwide. 
Data from the GLOBOCAN [1] database shows gastric cancer to be the third 
leading cause of cancer mortality worldwide with 8.8% of total cancer mortality 
in 2012. This is despite a marked decline in incidence over the last few decades. 
The age adjusted incidence rate of gastric cancer in South Africa is 5.09/100 
000, making it the fifth most common cancer in this country.  The prognosis of 
gastric cancer is poor with 2002 TNM stage groupings showing a 58% 5 year 
overall survival for stage IB disease, 34% for stage II, 20% for stage IIIA and 8% 
for stage IIIB [2, 3]. This burden of mortality has encouraged the study of 
surgical technique as well as adjuvant therapies in the hope of improving these 
outcomes. The role of surgery and adjuvant chemoradiation was established as 
one of the primary approaches to the management of nonmetastatic gastric 
cancer in the Intergroup 0116 study [4]. It was shown that post operative 
chemoradiation improved median overall survival from 27 months to 36 
months. In this trial, a two dimensional conventional approach was used to 
deliver radiotherapy (45Gy in 1.8Gy fractions delivered daily five times per 
week). Acute grade III and grade IV toxicities were reported in 41% and 32% 
respectively. Late toxicity has not been reported. The proven clinical benefit for 
radiotherapy is therefore tempered by this toxicity.  
The target volume used in post operative radiotherapy for gastric cancer 
includes regional lymph nodes, the tumour bed, site of anastomosis and gastric 
remnant if any. The planning target volume (PTV) therefore encroaches on 
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surrounding critical organs including the liver, spinal cord, left and right kidney. 
The need for increased conformity and organ at risk sparing in adjuvant 
radiotherapy of gastric cancer has prompted interest in and investigation of 
other radiotherapy techniques. Prior dosimetric studies have been undertaken 
to evaluate the potential benefit of three dimensional conformal radiotherapy 
(3DCRT), intensity modulated (IMRT) and volumetric modulated arc therapy 
(VMAT) [5-13]. These have shown mixed results. Whilst the balance of evidence 
favours a dosimetric advantage for 3DCRT over two dimensional conventional 
radiotherapy, the benefit of IMRT over 3DCRT is less assured. Certain studies 
suggest a dosimetric benefit for IMRT over 3DCRT whilst others propose no 
benefit or only a marginal benefit. In addition, little data exists regarding the 
use of VMAT in adjuvant radiotherapy of gastric cancer [5]. 
The purpose of this study is to dosimetrically evaluate and compare VMAT and 
3DCRT in adjuvant radiotherapy of gastric cancer. PTV coverage and organ at 
risk sparing are reported. 
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Literature Review 
The role of radiotherapy in gastric cancer in the post operative setting was 
established by Macdonald et al [4]. In this seminal paper, 556 pts with T1-
T4,N0-1 gastric or esophagogastric junction tumors were randomised to 
observation or chemoradiation postoperatively. The majority were T3 or T4 
tumors (68%) and 85% were node positive. The benefit for adjuvant 
radiotherapy was evidenced by a 5 year overall survival benefit of 43% versus 
28% in the observation group. An in depth analysis of this and other studies 
evaluating the role of adjuvant radiotherapy in gastric cancer is beyond the 
scope of this paper but this important data is presented here to provide the 
necessary context. In this study, a two dimensional conventional technique was 
used to deliver the radiotherapy. Since then, other techniques have been 
employed in adjuvant radiotherapy of gastric cancer with the aim of achieving 
improved conformity and organ at risk sparing [5-13]. These include three 
dimensional conformal radiotherapy, intensity modulated radiotherapy and 
volumetric modulated arc therapy. The primary objective of this literature 
review is to critically assess the published literature with regard to adjuvant 
radiotherapy techniques used in gastric cancer. Specifically, dosimetric 
evaluation for target volume coverage and organ at risk sparing was sought. It 
was expected and subsequently proven that little evidence existed in the 
literature regarding volumetric modulated arc therapy in adjuvant 
radiotherapy of gastric cancer. Comparatively, though still limited, more 
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evidence was available with respect to other techniques including three 
dimensional conformal radiotherapy and intensity modulated radiotherapy. 
An online search using University of Cape Town libraries was performed. The 
keywords chosen included “radiotherapy” and “gastric”. 48 results were 
obtained. Inclusion criteria included studies which evaluated radiotherapy 
techniques in the adjuvant setting for gastric cancer. All studies which 
evaluated dosimetric benefit, regardless of technique, were included. Exclusion 
criteria included studies evaluating non adenocarcinoma histology, non gastric 
primary tumors, clinical studies that did not specifically evaluate dosimetric 
differences between radiotherapy techniques, intraoperative radiotherapy and 
radiotherapy not given in the adjuvant setting.  
As noted, the available literature evaluating volumetric modulated arc therapy 
in adjuvant radiotherapy for gastric cancer is scant. In the Wang study [5], 12 
patients were retrospectively analysed with comparison made between single 
arc VMAT, 3DCRT and IMRT. They reported improved target volume conformity 
for VMAT and IMRT compared to 3DCRT, with a superior conformity index 0.82 
± 0.03 and 0.82 ± 0.03 for IMRT and VMAT respectively compared to 0.69 ± 0.03 
for 3DCRT, p < 0.001. The maximum and mean doses to the target volume were 
significantly higher for both VMAT and IMRT. The mean Dmax for VMAT and 
IMRT was 57.86Gy and 57.24Gy respectively. With regard to organ at risk 
sparing, they showed benefit for VMAT and IMRT for both the liver and left 
kidney over 3DCRT. The left kidney mean dose, V20 and V30 as well as the liver 
V20 and V30 were all reduced for VMAT and IMRT over 3DCRT. No significant 
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difference was seen for liver mean dose. Of note in this study, the benefit of 
VMAT over IMRT was limited to the reduced V20 of the liver. The Wang study 
[5] is one of the first papers to evaluate the role of VMAT in adjuvant
radiotherapy of gastric cancer and this initial reported experience lays down a 
marker for comparison and further study.  
With respect to 3DCRT in adjuvant radiotherapy for gastric cancer, there is 
conflicting evidence in the literature. A systematic review published by 
Morganti [6] suggests that the advantage of 3DCRT over conventional 
radiotherapy is not proven. In terms of target volume coverage, a “minimal 
advantage” was seen for 3DCRT. In terms of organs at risk, the liver was better 
spared by conventional radiotherapy. The left kidney was better spared by 
3DCRT and the right kidney was equivocal between the two techniques. In 
contrast to these findings, Leong et al (2005) demonstrated improved target 
volume coverage and reduced doses for the right and left kidney and spinal 
cord for 3DCRT compared to conventional radiotherapy with an antero-
posterior postero-anterior (AP/PA) beam arrangement [7]. In this study, a split 
field monoisocentric technique was employed. 99% of the planning target 
volume received 95% of the prescribed dose with the conformal technique 
compared to 93% with the 2D technique. Of note here is coverage of the PTV 
with 98% of the prescribed dose - 95% for the conformal technique and, 
significantly inferior, 71% for the AP–PA technique. The spinal cord dose was 
reduced with 3DCRT. The doses to one third and two thirds of the spinal cord 
were 17 and 3 Gy, respectively, for the conformal technique, and 45 and 6 Gy for 
the AP–PA technique. Sparing of the right kidney was achieved with 3DCRT 
13 
with one third and two thirds of the right kidney receiving 18 and 6 Gy, 
respectively, for the conformal technique, and 35 and 4 Gy for the AP–PA 
technique. Similarly, sparing of the left kidney was achieved with 3DCRT – 18Gy 
to one third and 5Gy to two thirds for 3DCRT and 40Gy to 1/3rd and 5Gy to 
2/3rd for the conventional technique. The dose to the liver was higher with 
3DCRT compared to the AP/PA technique though still below tolerance (mean 
dose 22Gy for 3DCRT and 14Gy for AP-PA). These results clearly demonstrate a 
dosimetric benefit for 3DCRT with improved target volume coverage and organ 
at risk sparing for the defined structures. These findings have been replicated 
by others. Soyfer et al [11] showed a dosimetric benefit for 3DCRT in terms of 
kidney sparing. In this study, three arms were compared i.e. conventional AP-
PA, 4 field box technique and “experimental” noncoplanar 3DCRT. A distinction 
was made for dosimetric purposes between the higher dose kidney (HDK) and 
the lower dose kidney (LDK). The mean dose to the higher dose kidney was 
19.25 Gy in the experimental arm, 20.58 Gy with the four-field box technique 
and 24.59 Gy with AP–PA technique. Comparison of the mean dose between the 
experimental plan and the AP–PA plan showed a statistically significant benefit 
for the experimental plan. In terms of the other organs at risk, a benefit for the 
spinal cord was seen with the 3DCRT plan. In a similar fashion to Leong, Soyfer 
showed decreased dose to the liver with the conventional AP-PA technique. In 
summary, therefore, there is a balance of evidence favouring a dosimetric 
benefit for 3DCRT over a conventional 2D technique. The systematic review 
discussed, however, points to a “minimal advantage” offered by 3DCRT. 
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With regard to IMRT in adjuvant radiotherapy for gastric cancer, there is again 
limited and conflicting evidence. Milano et al (2006) compared conventional 
AP-PA (2 field), 3 field 3DCRT and IMRT techniques dosimetrically and also 
reported early clinical outcomes in seven patients [8]. In this study, the 
prescription dose was 50.4Gy, escalated from the standard 45Gy based on the 
Intergroup trial [4]. IMRT was shown to be superior to 3DCRT with reduced 
dose to the liver and right kidney. The right kidney mean dose was 26.7% 
(percentage of prescription dose) in the 3DCRT arm compared to 18.9% for 
IMRT. The right kidney volume receiving greater than threshold dose (V20) also 
showed benefit for IMRT – 20.9% for 3DCRT compared to 11.6% for IMRT. 
Similarly, the mean dose to the liver was reduced with IMRT (44.6% of 
prescription dose compared to 67.9% for 3DCRT). The liver volume receiving 
greater than the threshold dose (V30) was also reduced with 63.6% for 3DCRT 
compared to 18.9% for IMRT. Planning target volume coverage was evaluated 
by mean PTV dose and the volume receiving 55.4Gy and maximum dose. The 
IMRT plans had a higher mean PTV dose as well as volume receiving >55.4Gy, 
though neither finding was statistically significant. The maximum dose with 
IMRT was, however, increased and this was statistically significant compared to 
the 3DCRT technique and the two field technique. The Milano paper went on to 
report clinical outcomes, specifically acute toxicities, in this group. Despite a 
higher prescription dose than that used in the Intergroup trial, there was no 
grade 3 or worse acute toxicity.  In addition, all patients completed their 
planned course of chemoradiotherapy. This is in contrast to the Intergroup trial 
in which 33% experienced grade 3 or worse gastrointestinal toxicity and 64% 
completed treatment uninterrupted. The Milano paper, therefore, suggests both 
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a dosimetric and clinical benefit for IMRT over other techniques including 
3DCRT.  
Minn [9] adds weight to the argument for the benefit of IMRT over 3DCRT. In 
similar fashion to the Milano paper, both dosimetric and clinical outcomes were 
reported. In this study, 57 patients were evaluated – 26 of whom received 
3DCRT and 31 received IMRT.  Of interest here, the mean kidney dose (bilateral 
kidneys) was increased in the IMRT group compared to the 3DCRT group 
(13.9Gy vs 11.1Gy, p = 0.05) but the V20 was reduced for the IMRT group. The 
V20 for the IMRT group was 17.5% compared to 22% for 3DCRT with a p value 
of 0.17. In this study, serum creatinine was measured and compared pre-
treatment to most recent. The median creatinine was unchanged in the IMRT 
group (0.8mg/dl) but increased in the 3DCRT group from 0.8mg/dl to 1.0 
mg/dl. This was statistically significant with a p value of 0.02. This suggests that 
the V20 is perhaps a more useful dosimetric endpoint than mean dose in 
predicting clinical outcomes. Benefit for the liver as an organ at risk was also 
shown in this study with the median liver mean dose for IMRT being 13.6Gy 
compared to 18.6Gy for 3DCRT. p=0.19. The median liver V30 was 16.1% for 
IMRT and 28% for 3DCRT (p < 0.001).  
In terms of clinical outcomes, no difference was seen in 2 year overall survival 
or locoregional recurrence. Grade 2 acute toxicity was similar between the two 
groups although more treatment interruptions were required in the 3DCRT 
group. This paper therefore shows a dosimetric benefit for the liver and 
possible benefit for the kidneys with IMRT. An important limitation in this 
study, however, is the fact that IMRT and 3DCRT plans and dose volume 
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histograms were not compared for individual patients but rather as two groups. 
As a result, potential variables were inherent including target volume definition, 
field design, patient anatomy and the individual preferences of treating 
physicians.  PTV coverage was not evaluated in this study.  
Ringash [12] published an article which sought to address the potential 
advantage of IMRT over 3DCRT using somewhat dissimilar methods to the 
previously mentioned papers. In this study of twenty patients, patients who had 
previously received 3DCRT were replanned using IMRT. Two blinded radiation 
oncologists were then presented with dose volume histograms and organ dose 
summaries. Dose distributions and digitally reconstructed radiographs were 
not provided. IMRT was the preferred plan in 89% of cases. The blinded 
reviewers felt that IMRT provided better planning target volume coverage in 
86% of cases. Organs at risk were also thought to be spared preferentially with 
IMRT – 74% of cases for spinal cord, 69% of cases for kidneys, 71% of cases for 
liver and 69% of cases for the heart. These statistics are difficult to relate to the 
available literature as they reflect distinctly dissimilar endpoints from those 
published in other studies. However, these findings do add weight to the 
argument in favour of benefit of IMRT over 3DCRT. This paper does also report 
the median doses received by the organs at risk (OAR) – dose to 20%, 50% and 
80% of the volume of each OAR is presented. Using D50 as a surrogate, dose to 
50% of the liver (17.29 vs. 27.97), left kidney (15.50 vs. 16.06 Gy) and heart 
(12.89 vs. 15.50 Gy), were lower with IMRT than with the conformal plans. 
17 
The study by Chung [13] also supports the dosimetric benefit of IMRT over 
3DCRT. In this study of ten patients, IMRT had an increased PTV V45 (volume of 
the PTV receiving >45Gy) of 95% versus 72% for 3DCRT. No difference was 
noted for the left and right kidneys between 3DCRT and IMRT. The liver was 
preferentially spared with IMRT – V30 of 24.5% for IMRT versus 40.2% for 
3DCRT with a p value <0.001. The mean dose was also improved with IMRT 
22.7Gy versus 26.3Gy (p <0.001). Of note in this study, the plans were also sent 
to a centre experienced in IMRT, namely the University of California San 
Francisco (UCSF) for replanning. UCSF was able to achieve lower left kidney 
V20 and right kidney V20 than the IMRT plans of Chung. They also achieved 
lower liver mean dose than the IMRT plans of Chung. This study therefore 
highlights two aspects. Firstly, the benefit of IMRT over 3DCRT is shown in 
terms of liver sparing and PTV coverage. It must be stated here, however, that 
the endpoint chosen to evaluate PTV coverage is not as robust as, for example, 
indexes evaluating conformity, homogeneneity and uniformity. Secondly, the 
improvement in plans achieved by an experienced centre demonstrates the 
dependence of IMRT planning on individual users. This effect cannot be 
underestimated when interpreting dosimetric data that originates in many 
different sites with varying levels of experience and expertise.  
The Alani [10] article of 2009 compared 3DCRT and IMRT dosimetrically with 
similar endpoints to those mentioned in the other studies. 14 patients were 
included. All these patients had been treated with a noncoplanar four field 
arrangement. This is a departure from the coplanar approach utilised in other 
trials. IMRT plans were then generated for comparison. PTV coverage was 
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“satisfactory” for both approaches based on 95% isodose coverage. In this trial, 
a clinical distinction was made between high and low dose kidney, not simply 
left and right. Mean kidney dose to the high dose kidney was 12.8Gy for IMRT 
and 25.6Gy for 3DCRT. The V20 for the high dose kidney was 17% for IMRT 
compared to 39% for 3DCRT. In terms of the low dose kidney, the mean dose 
was 11.3Gy for IMRT versus 21.2Gy for 3DCRT, with a V20 of 7% for IMRT and 
17% for 3DCRT. These results depict a benefit for IMRT over 3DCRT in terms of 
kidney sparing. Despite the statistical significance shown, the authors do 
question however the clinical relevance of this benefit. Of course, this can only 
be evaluated in a clinical study and this question remains unanswered. Of note 
in this paper is the mean dose to the liver. They achieved a mean dose of 31Gy 
for IMRT and 25Gy for 3DCRT. The statistical relevance of, never mind the 
reasons for, this finding is not discussed in the paper. In summary, the authors 
note that IMRT confers only a “marginal benefit” over 3DCRT and should be 
considered only in those patients with underlying kidney disease or risk factors 
for its development. The authors also assert that the noncoplanar beam 
arrangement approach is a “valuable tool” and suggest that the benefit of IMRT 
over 3DCRT seen in other reports, as discussed previously, “may have been 
exaggerated”.  
All studies with dosimetric comparisons were included regardless of the 
methods of comparison. A challenge faced when interpreting the available data, 
therefore, was the variety of methods used in the different studies to evaluate 
target volume coverage and organ at risk sparing. The endpoints used were 
heterogeneous. Evaluation and comparison of target volume coverage was 
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variably done on the basis of percentage of the target volume covered by the 
95% isodose line, conformity, uniformity and homogeneity indexes. The 
parameters used to compare organ at risk sparing also varied. This makes cross 
trial comparison and interpretation of the data difficult – a standard template of 
comparison with predefined parameters would make analysis of the data as a 
whole more meaningful. However, the comparative value for individual articles 
remains useful. 
In summary, whilst the balance of evidence favours a dosimetric advantage for 
3DCRT over two dimensional conventional radiotherapy, the benefit of IMRT 
over 3DCRT is less certain. Little data exists in the literature regarding the use 
of volumetric modulated arc therapy in gastric cancer and the data presented 




Eight patients were identified who met the inclusion criteria. This included 
patients seen at the Department of Radiation Oncology, Groote Schuur Hospital 
between 2009-2013 with pathologically proven gastric adenocarcinoma. All 
patients had undergone surgery as the primary modality of treatment followed 
by adjuvant three dimensional conformal radiotherapy. Exclusion criteria 
included patients with metastatic disease, patients who received two 
dimensional conventional radiotherapy, non adenocarcinoma histology and 
oesophageal or oesophagogastric junction tumors.  
These patients had all been previously treated with 3DCRT using the Varian ® 
Clinac 23Ex and treatment planning was done using the Pinnacle ® treatment 
planning software. The same CT data sets and segmented structures, including 
planning target volume and organs at risk, were duplicated to create a template 
for this analysis. The prescribed dose-fractionation schedule conformed to the 
international standard of 45Gy in 1.8Gy fractions described in Intergroup 0116 
[4]. The 3DCRT plans typically consisted of 3 and 4 coplanar fields optimised by 
forward planning. Dose prescription was to the International Commission on 
Radiation Units and Measurements (ICRU) reference point. Beam weighting, 
energy, angles and multileaf collimator position were optimised for each of 
these treatment plans.  All patients had an assessment of renal function with 
pre-treatment glomerular filtration rate and renogram.  
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Volumetric modulated arc therapy plans were then generated for each of the 
patients within the Pinnacle ®  (Phillips Medical System, Madison, Wisconsin) 
treatment planning system. The dose prescription was to the ICRU reference 
point. Single arc VMAT was utilised for all patients. An initial template of 
constraints was applied to all eight patients. Modification of these constraints 
was done as necessary to optimise the plans i.e. minimise dose to organs at risk 
without compromising PTV coverage.  The planning criteria for organs at risk 
conformed closely to QUANTEC  tolerance guidelines. The initial constraints 
applied were as follows: 
1. PTV – 95% prescribed dose to 98% of the PTV. Dmax 107% of
prescribed dose.
2. Liver – V30 <30%
3. Left kidney – V23 <30%
4. Right kidney – V23 <30%
5. Spinal cord – Dmax <45Gy
The parameters used to compare planning target volume coverage of the 
3DCRT and VMAT plans included conformity index, uniformity index, 
homogeneity index, mean dose, maximum dose and percentage of target 
volume receiving at least 95% of prescribed dose (TV95%). The indexes are 
defined as follows: 
1. Conformity index – defined by the following formula. (TV95/TV) x
(TV95/V95). TV95 is the volume of the target covered by the 95%
isodose curve. TV is the total target volume. V95 is the volume of tissue
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covered by the 95% isodose line. The conformity index ranges from 0 to 
1, with 1 being the ideal value [14]. 
2. Uniformity index – defined as D5/D95. D5 is the minimum dose to 5% of
the PTV. D95 is the minimum dose to 95% of the PTV. The lower the
index, the more uniform the plan [15].
3. Homogeneity index – defined as the difference in PTV dose between D1
and D99 divided by the prescription dose. The lower the index, the more
homogenous the plan [16-18].
The parameters used to compare organ at risk sparing for 3DCRT and VMAT 
included maximum dose, mean dose and percentage of volume of organ at risk 
(OAR) receiving a dose more than its tolerance limit as defined by QUANTEC. 
This was done for each organ at risk, namely left and right kidney, liver and 
spinal cord. The specific parameters were as follows: 
1. Liver – Dmax (maximum dose), Dmean (mean dose to the organ), V30
(volume of the organ receiving more than 30Gy)
2. Right and left kidney – Dmax, Dmean, V23 (volume of the organ
receiving more than 23Gy)
3. Spinal cord - Dmax
Dose volume histograms were also used to compare treatment plans. All data 
was captured into an electronic Microsoft Excel ® database. Personal identifiers 
were removed. Descriptive statistics including mean and standard deviation 
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was used to summarise results. Statistical analysis was performed with a paired 
t-test and a p value of p<0.05 was set for statistical significance.
24 
Results 
Both the 3DCRT and VMAT approaches produced acceptable plans, both in 
terms of PTV coverage and organ at risk tolerances i.e. dose distributions and 
dose volume histograms were satisfactory for all plans.  
In terms of PTV coverage, VMAT was shown to be superior with respect to the 
conformity and uniformity indexes, TV95 as well as maximum dose. No 
difference was seen with regard to the homogeneity index or PTV mean dose: 
1. The mean conformity index for 3DCRT was 0.73 with 95% CI 0.71-0.75
and the mean conformity index for VMAT was 0.77 with a 95% CI 0.73-
0.81. This was statistically significant with a p value of 0.02.
2. The mean uniformity index for 3DCRT was 1.13 (95% CI 1.11-1.14)
compared to a mean of 1.10 for VMAT (95% CI 1.09-1.11), p = 0.021.
3. The TV95 for VMAT was superior with a mean 3DCRT TV95 of 96.79
(95% CI 95.72-97.87) compared to the VMAT TV95 mean of 97.53 (95%
CI 96.8-98.26) with a p 0.0049.
4. In terms of maximum dose (Dmax), VMAT achieved a statistically
significant lower dose. The 3DCRT mean PTV Dmax was 112% (95% CI
109.8-114.2) compared to VMAT mean 110.5% (95% CI 108.9-112), p =
0.005.
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5. In terms of the homogeneity index, no difference was seen between
3DCRT and VMAT. The mean homogeneity index for 3DCRT was 0.17
(95% CI 0.14-0.21) and VMAT was 0.17 (95% CI 0.14-0.20) p = 0.54.
6. No difference was seen in the PTV mean dose – 103.4% (95% CI 102.4-
104.4) for 3DCRT and 104% (95% CI 102.9-105%) for VMAT, p = 0.11.
Table 1: Comparison of the PTV parameters 
3D-CRT VMAT 
Mean (95% CI) Mean (95% CI) p Value 
Conformity Index 0.73 (0.71-0.75) 0.77 (0.73-0.81) 0.02 
Uniformity Index 1.13 (1.11-1.14) 1.10 (1.09-1.11) 0.021 
Homogeneity Index 0.17 (0.14-0.21) 0.17 (0.14-0.20) 0.54 
TV95 96.79% (95.72-97.87) 97.53% (96.8-98.26) 0.0049 
Dmax 112% (109.8-114.2) 110.5% (108.9-112) 0.005 
PTV Mean 103.4% (102.4-104.4) 104% (102.9-105) 0.11 
CI = confidence interval 
Conformity index, uniformity index, homogeneity index and TV95 calculated as described under Methods 
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In terms of organ at risk sparing, VMAT was superior to 3DCRT for the liver 
Dmax and V30 though no difference was shown for Dmean. No difference was 
seen for the left and right kidney or spinal cord: 
1. Liver – the mean Dmax for 3DCRT was 49.7Gy (95% CI 48.6Gy-50.8Gy)
compared to the VMAT mean of 48.9Gy (95% CI 48Gy-49.9Gy), p = 0.01.
The V30 for VMAT was also superior to 3DCRT. The 3DCRT mean V30
was 34.2Gy (95% CI 25.9 – 42.6Gy) compared to 24.2Gy for VMAT (95%
CI 21.2-27.2Gy), p = 0.013. No statistically significant difference was
shown in terms of the mean dose to the liver, with 3DCRT achieving a
mean of 22.1Gy (95% CI 20.4 – 23.8Gy) and VMAT achieving a mean of
21.7Gy (95% CI 20.2 – 23.2Gy), p = 0.38.
2. Right kidney – no difference was shown for any of the defined
parameters. The mean Dmax for 3DCRT was 33.1Gy (95% CI 22.9 –
43.3Gy) compared to the VMAT Dmax of 34.3Gy (95% CI 25.8 – 42.7Gy),
p= 0.39. The mean dose for 3DCRT was 10.2Gy (95% CI 5.9 – 14.4Gy)
compared to VMAT 11.4Gy (95% CI 7.4 -15.4Gy) with a nonsignificant
difference. The mean for both 3DCRT and VMAT are well within
tolerance. The 3DCRT V23 was 6.8Gy compared to 8.6Gy for VMAT
(nonsignificant).
3. Left Kidney – the clinical relevance of the defined parameters in the left
kidney should be understood in context. In terms of the planning
approach for both the forward and inverse plans in the present study,
the typical dose constraints one would apply were purposefully
disregarded. This is based on the clinical decision to accept a higher dose
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to the left kidney with the intention of maximal sparing of the 
contralateral kidney. No difference was seen in terms of Dmax or V23. 
The 3DCRT mean Dmax was 48Gy compared to 47.8Gy, a nonsignificant 
difference. The V23 for 3DCRT was 70.7Gy and 64.7 for VMAT, 
statistically nonsignificant. A benefit for the left kidney mean dose was 
shown for VMAT over 3DCRT. The mean dose achieved with 3DCRT was 
30.6Gy (95% CI 21 – 40.3Gy) compared to 28.6Gy (95% CI 18.9 – 38Gy), 
p = 0.02.  
4. Spinal cord – no difference was seen for the spinal cord Dmax, with
34.2Gy (95% CI 25.9 – 42.4Gy) for 3DCRT versus 40.1 (95% CI 37 –
43.2Gy) for VMAT, a nonsignificant difference.
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Table 2: Comparison of the OAR parameters 
3D-CRT VMAT 
Mean (95% CI) Mean (95% CI) p Value 
Liver 
V30 Ψ 34.2% (25.9-42.6) 24.2% (21.2-27.2) 0.013 
Dmax 49.7Gy (48.6-50.8) 48.9Gy (48-49.9) 0.01 
Mean 22.1Gy (20.4-23.8) 21.7Gy (20.2-23.2) 0.38 
Right kidney 
V23  ♯ 6.8% (1.3-14.9) 8.6% (2.2-14.9) 0.246 
Dmax 33.1Gy (22.9-43.3) 34.3Gy (25.8-42.7) 0.39 
Mean 10.2Gy (5.9-14.4) 11.4Gy (7.4-15.4) 0.06 
Left kidney 
V23 ♯ 70.7% (46.6-94.9) 64.7% (35.4-94.1) 0.104 
Dmax 47.9Gy (46.9-49) 47.8Gy (47.1-48.6) 0.707 
Mean 30.67Gy (21-40.34) 28.6Gy (19-38.2) 0.02 
Spinal Cord 
Dmax 34.2Gy (25.9-42.4) 40.1Gy (37-43.2) 0.052 
CI = confidence interval 
 Ψ The volume of the liver that received more than 30Gy 
♯ The volume of the kidney that received more than 23Gy
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Representative isodose distributions and dose volume histograms are shown 
below for comparative purposes. 
Figure 1. 3DCRT - Isodose curves and beam arrangement in axial (A), sagittal 









Figure 3. Dose volume histogram comparing 3DCRT (thin solid) and VMAT 
(thick solid)  in a representative patient.  
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Discussion 
Primary surgery and adjuvant chemoradiation for gastric cancer is an 
established approach since Macdonald’s seminal paper [4]. Following this, the 
Smalley consensus report advocated parallel opposed fields as “the most 
practical arrangement for the overwhelming majority of postoperative adjuvant 
radiotherapy cases” [19]. However, given the rate of acute grade III and IV 
toxicities, specifically 41% and 32% in the Macdonald trial, in addition to poor 
survival rates in gastric cancer, efforts have been made to improve the 
radiotherapy component of gastric cancer treatment. Subsequent studies 
evaluating different techniques of radiotherapy, including three dimensional 
conformal radiotherapy and intensity modulated radiotherapy, have yielded 
mixed results [5-13].  Whilst the balance of evidence favours a dosimetric 
advantage for 3DCRT over two dimensional conventional radiotherapy, the 
benefit of IMRT over 3DCRT is less certain. Little data exists in the literature 
regarding the use of volumetric modulated arc therapy in gastric cancer. The 
data presented by Wang [5] is, to our knowledge, the first study to evaluate the 
role of VMAT in adjuvant radiotherapy of gastric cancer. 
Currently at our institution, three dimensional conformal radiotherapy is 
offered to all gastric cancer patients in the adjuvant setting. The dosimetric 
benefits shown in this study contend that VMAT is superior to three 
dimensional conformal radiotherapy for adjuvant radiotherapy of gastric 
cancer. We observed a benefit for VMAT with superior PTV coverage, as 
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evidenced by improved conformity, uniformity, volume of PTV covered by the 
95% isodose and a lower Dmax. In addition, improved organ at risk sparing, 
specifically for the liver, was achieved with VMAT. This was shown in terms of a 
reduced V30 and Dmax. No difference was observed with regard to the other 
organs at risk, namely left and right kidney and spinal cord. In comparison to 
Wang, we have similarly confirmed the benefit of VMAT in terms of PTV 
coverage and liver sparing. In contrast, however, we were not able to show a 
dosimetric benefit for either the left or right kidney with VMAT. The basis for 
this lack of benefit may include several reasons. As demonstrated by Chung, 
improvement in plans can be achieved by a centre more experienced in 
intensity modulated radiotherapy [13]. Secondly, the clinical decision to accept 
doses beyond tolerance to one kidney, with the express intention of maximal 
sparing of the contralateral kidney, must be factored in. Cross trial comparison 
must take these aspects into account.  
The role of radiotherapy in gastric cancer must also be considered in a resource 
constrained setting. In an environment where time on the Linac is precious, the 
benefit of reduced treatment times is an important factor. Radiotherapy 
departments such as ours who face these challenges would welcome any 
potential gains that VMAT might offer in this regard.  Whilst treatment times 
might be reduced, however, the increased burden of quality assurance for 
VMAT compared to 3DCRT would be an equally important factor to consider in 
a resource constrained environment. Clinical studies are needed to further 
evaluate these particular aspects.  
34 
Based on these observations, the possible clinical benefits must be considered. 
Whilst these benefits cannot be truly known outside a clinical trial, the potential 
for reduced treatment related toxicity is clear. In addition, there is also 
potentially less need to sacrifice, possibly tumoricidal, total dose to meet 
surrounding organ at risk tolerances. Indeed, there is the possibility of dose 
escalation with more conformal techniques. Situations which warrant this 
consideration include incomplete resection or nodal extracapsular extension. In 
a disease fraught with poor outcomes and significant treatment related 
morbidity, any meaningful improvement in radiotherapy technique and 
delivery will be welcomed. Volumetric modulated arc therapy in the adjuvant 
setting for gastric cancer warrants further clinical study.  
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article. The cover page will also display the journal logo, article title and citation 
details. The image may either be a figure from your manuscript or another 
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relevant image. You must have permission from the copyright to reproduce the 
image. Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster 
image). 
Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs 
and screen dumps), JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals 
(i.e. Table 1, 2, 3 etc.). Tables should also have a title (above the table) that 
summarizes the whole table; it should be no longer than 15 words. Detailed 
legends may then follow, but they should be concise. Tables should always be 
cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into 
the end of the document text file, in A4 portrait or landscape format. These will 
be typeset and displayed in the final published form of the article. Such tables 
should be formatted using the 'Table object' in a word processing program to 
ensure that columns of data are kept aligned when the file is sent electronically 
for review; this will not always be the case if columns are generated by simply 
using tabs to separate text. Columns and rows of data should be made visibly 
distinct by ensuring that the borders of each cell display as black lines. Commas 
should not be used to indicate numerical values. Color and shading may not be 
used; parts of the table can be highlighted using symbols or bold text, the 
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meaning of which should be explained in a table legend. Tables should not be 
embedded as figures or spreadsheet files. 
Larger datasets or tables too wide for a landscape page can be uploaded 
separately as additional files. Additional files will not be displayed in the final, 
laid-out PDF of the article, but a link will be provided to the files as supplied by 
the author. 
Tabular data provided as additional files can be uploaded as an Excel 
spreadsheet (.xls ) or comma separated values (.csv). As with all files, please use 
the standard file extensions. 
Preparing additional files 
Although Radiation Oncology does not restrict the length and quantity of data 
included in an article, we encourage authors to provide datasets, tables, movies, 
or other information as additional files. 
Please note: All Additional files will be published along with the article. Do not 
include files such as patient consent forms, certificates of language editing, or 
revised versions of the main manuscript document with tracked changes. Such 
files should be sent by email to radiationoncology@biomedcentral.com, quoting 
the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should 
be included as additional files. Since many weblinks and URLs rapidly become 
broken, Radiation Oncology requires that supporting data are included as 
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additional files, or deposited in a recognized repository. Please do not link to 
data on a personal/departmental website. The maximum file size for additional 
files is 20 MB each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final 
published article as supplied by the author. We recommend CSV rather than 
PDF for tabular data. 
Certain supported files formats are recognized and can be displayed to the user 
in the browser. These include most movie formats (for users with the Quicktime 
plugin), mini-websites prepared according to our guidelines, chemical structure 
files (MOL, PDB), geographic data files (KML).  
If additional material is provided, please list the following information in a 
separate section of the manuscript text: 
 File name (e.g. Additional file 1)
 File format including the correct file extension for example .pdf, .xls,
.txt, .pptx (including name and a URL of an appropriate viewer if
format is unusual)
 Title of data
 Description of data
Additional files should be named "Additional file 1" and so on and should be 
referenced explicitly by file name within the body of the article, e.g. 'An 
additional movie file shows this in more detail [see Additional file 1]'. 
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Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and 
should be viewable using free or widely available tools. The following are 
examples of suitable formats. 
 Additional documentation
o PDF (Adode Acrobat)
 Animations
o SWF (Shockwave Flash)
 Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
 Tabular data
o XLS, XLSX (Excel Spreadsheet)
o CSV (Comma separated values)
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way 
that they will be browsable from within the full text HTML version of the article. 
In order to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or
index.htm) in the root.
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2. Put all files necessary for viewing the mini-website within the
folder, or sub-folders.




website\images\picture.jpg") and no link is longer than 255
characters.
4. Access the index.html file and browse around the mini-website, to
ensure that the most commonly used browsers (Internet Explorer
and Firefox) are able to view all parts of the mini-website without
problems, it is ideal to check this on a different machine.
5. Compress the folder into a ZIP, check the file size is under 20 MB,
ensure that index.html is in the root of the ZIP, and that the file
has .zip extension, then submit as an additional file with your
article.
Style and language 
General 
Currently, Radiation Oncology can only accept manuscripts written in English. 
Spelling should be US English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are 
encouraged to be concise.  
64 
Radiation Oncology will not edit submitted manuscripts for style or language; 
reviewers may advise rejection of a manuscript if it is compromised by 
grammatical errors. Authors are advised to write clearly and simply, and to 
have their article checked by colleagues before submission. In-house 
copyediting will be minimal. Non-native speakers of English may choose to 
make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, 
please visit our page on Writing titles and abstracts for scientific articles.  
Tim Albert has produced for BioMed Central a list of tips for writing a scientific 
manuscript. American Scientist also provides a list of resources for science 
writing. For more detailed guidance on preparing a manuscript and writing in 
English, please visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined 
when first used and a list of abbreviations can be provided following the main 
manuscript text. 
Typography 
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
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 Use hard returns only to end headings and paragraphs, not to
rearrange lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the Radiation Oncology reference format.
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are
unable to reproduce a particular special character, please type out
the name of the symbol in full. Please ensure that all special
characters used are embedded in the text, otherwise they will
be lost during conversion to PDF.
Units 
SI units should be used throughout (liter and molar are permitted, however).´ 
